Search

Breast conservation therapy as an initial treatment did not compromise survival outcomes compared to mastectomy in breast cancer patients under the age of 35.

… Thursday, January 14, 2021 Survival outcomes in breast cancer patients under the age of 35 was not compromised in those who had initial conservation therapy versus those who had mastectomy, according to our retrospective study published recently in the International Journal of Radiation Oncology .  (

在 35 岁以下的乳腺癌患者中，与乳房切除术相比，保乳手术作为初始疗法并未损害患者的生存结局。

… Thursday, January 14, 2021 根据我们最近发表在 《国际放射肿瘤学杂志》 上的回顾性研究，对于 35 岁以下的乳腺癌患者，相较于接受乳房切除术的患者，接受初始保乳治疗的患者的生存结局并没有更差。  (1) 过去，与老年患者相比，40 岁以下的浸润性乳腺癌女性患者的总生存率 (OS) 更差，复发率更高，  (2) ,   (3) ,   (4) 因此这些患者接受更高强度的治疗，如乳房切除术（而非保乳手术）联合辅助治疗。 之前的研究也发现，年轻的乳腺癌患者的结局更差。 然而，在这些研究中，研究时间间隔以及对“年轻”或“非常年轻”患者组和老年对照组的定义各不相同，其中一些还包括

Three 2010 summer students won poster awards at the Annual Biomedical Research Conference for Minority Students in November.

… Wednesday, December 1, 2010 Three 2010 summer students — Jeannie Camarillo, Mariela Martinez Rivera, and Cynthia Sandoval — won poster awards at the Annual Biomedical Research Conference for Minority Students in November. Over 1,200 posters were submitted and only 140 awards presented.

Carl Granum tells the story of his diagnosis and treatment for a desmoplastic small round cell tumor, a type of sarcoma that typically begins in the abdomen or pelvis.

… Friday, January 19, 2018 Summary Carl Granum was a college athlete in Iowa when he was diagnosed with a desmoplastic small round cell tumor , a type of sarcoma that typically begins in the abdomen or pelvis. In general, sarcomas are cancers in bones, muscles, and connective tissue throughout the body

— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.

… Sunday, March 31, 2019 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest

The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.

… Thursday, November 20, 2025 On November 19, 2025, the U.S. Food and Drug Administration (FDA)  granted full approval  to the targeted immunotherapy drug  tarlatamab (Imdelltra ® )  for treating adults with advanced small cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. The approval

In a plenary presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, Dr. Dana Pe’er highlighted three recent research collaborations between her lab and other labs at MSK that have shed new light on the ability of cancer cells to adapt and spread.

… Tuesday, April 9, 2024 About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain. And metastasis relies on cancer cells’ ability to adapt to different

The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a 468-gene oncopanel intended to detect gene mutations and other critical genetic aberrations in both rare and common cancers.

… Wednesday, November 15, 2017 The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT ™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of

For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.

… Sunday, April 27, 2025 For decades, cancers with mutations in the gene  KRAS (KAY-ras) were considered “undruggable.”  KRAS  mutations are found in more than 20% of cancers. They are most common in  lung cancer ,  pancreatic cancer , and  colorectal cancer . Nearly four years ago, the first drug was

Por primera vez, un fármaco dirigido está mostrando resultados prometedores en el tratamiento del cáncer pulmonar de células no pequeñas causado por una mutación llamada KRAS-G12D.

… Sunday, April 27, 2025 Durante décadas, los casos de cáncer con mutaciones en el gen  KRAS  se consideraron “no tratables con fármacos”. Las mutaciones en KRAS  se encuentran presentes en más del 20 % de los casos de cáncer. Son más comunes en el  cáncer pulmonar ,  el cáncer de páncreas y el  cáncer